One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study

Bone Loss After Romosozumab/Denosumab: Effects of Bisphosphonates

(2018) Anne M. Horne et al.   CALCIFIED TISSUE INTERNATIONAL

Romosozumab FRAME Study: A Post Hoc Analysis of the Role of Regional Background Fracture Risk on Nonvertebral Fracture Outcome

(2018) Felicia Cosman et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study

(2018) Michael R McClung et al.   JOURNAL OF BONE AND MINERAL RESEARCH

FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab

(2018) Felicia Cosman et al.   JOURNAL OF BONE AND MINERAL RESEARCH

High Imminent Vertebral Fracture Risk in Subjects With COPD With a Prevalent or Incident Vertebral Fracture

(2018) Mayke J van Dort et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial

(2018) Piet Geusens et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Treatment Sequence Matters: Anabolic and Antiresorptive Therapy for Osteoporosis

(2017) Felicia Cosman et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension

(2017) Steven R Cummings et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Greater Gains in Spine and Hip Strength for Romosozumab Compared With Teriparatide in Postmenopausal Women With Low Bone Mass

(2017) Tony M Keaveny et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis

(2017) Felicia Cosman et al.   MAYO CLINIC PROCEEDINGS

Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis

(2017) Kenneth G. Saag et al.   NEW ENGLAND JOURNAL OF MEDICINE

Imminent fracture risk

(2017) C. Roux et al.   OSTEOPOROSIS INTERNATIONAL

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS — 2016

(2016) Pauline M. Camacho et al.   Endocrine Practice

Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis

(2016) Paul D. Miller et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Romosozumab Improves Bone Mass and Strength While Maintaining Bone Quality in Ovariectomized Cynomolgus Monkeys

(2016) Michael S Ominsky et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Romosozumab Treatment in Postmenopausal Women with Osteoporosis

(2016) Felicia Cosman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Imminent risk of fracture after fracture

(2016) H. Johansson et al.   OSTEOPOROSIS INTERNATIONAL

Administration of romosozumab improves vertebral trabecular and cortical bone as assessed with quantitative computed tomography and finite element analysis

(2015) Christian Graeff et al.   BONE

Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial

(2015) Benjamin Z Leder et al.   LANCET

Romosozumab in Postmenopausal Women with Low Bone Mineral Density

(2014) Michael R. McClung et al.   NEW ENGLAND JOURNAL OF MEDICINE

Post-fracture pharmacotherapy for women with osteoporotic fracture: analysis of a managed care population in the USA

(2014) A. Wilk et al.   OSTEOPOROSIS INTERNATIONAL

Death, Debility, and Destitution Following Hip Fracture

(2013) Gabriel S. Tajeu et al.   JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES

Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass

(2011) Henry G. Bone et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Vertebral fracture assessment using a semiquantitative technique

(2010) Harry K. Genant et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody

(2010) Desmond Padhi et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Hip Fracture Patients at Risk of Second Hip Fracture: A Nationwide Population-Based Cohort Study of 169,145 Cases During 1977–2001

(2009) Jesper Ryg et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Clinical subsequent fractures cluster in time after first fractures

(2008) T A C M van Geel et al.   ANNALS OF THE RHEUMATIC DISEASES

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial

(2008) Paul D. Miller et al.   BONE